# Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)

> **NCT03976518** · PHASE2 · COMPLETED · sponsor: **Gruppo Oncologico Italiano di Ricerca Clinica** · enrollment: 43 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT03976518
- **Lead sponsor:** Gruppo Oncologico Italiano di Ricerca Clinica
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-07
- **Primary completion:** 2024-02-12
- **Final completion:** 2024-02-12
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2024-03-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03976518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03976518, "Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03976518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*